Ken Griffin Natera, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$97.75 - $129.67 $136,850 - $181,537	1,400 Added 2.95%	48,800 $6.2 Million
Q2 2024 Aug 14, 2024	BUY	$85.28 - $112.6 $2.1 Million - $2.77 Million	24,600 Added 107.89%	47,400 $5.13 Million
Q1 2024 May 15, 2024	BUY	$59.21 - $92.9 $1.24 Million - $1.95 Million	21,000 Added 1166.67%	22,800 $2.09 Million
Q4 2023 Feb 14, 2024	SELL	$37.55 - $62.64 $259,094 - $432,216	-6,900 Reduced 79.31%	1,800 $112,000
Q3 2023 Nov 14, 2023	SELL	$43.4 - $62.52 $963,480 - $1.39 Million	-22,200 Reduced 71.84%	8,700 $384,000
Q2 2023 Aug 14, 2023	BUY	$47.08 - $55.16 $37,664 - $44,128	800 Added 2.66%	30,900 $1.5 Million
Q1 2023 May 15, 2023	BUY	$36.57 - $58.29 $530,265 - $845,205	14,500 Added 92.95%	30,100 $1.67 Million
Q4 2022 Feb 14, 2023	SELL	$34.17 - $47.91 $78,591 - $110,192	-2,300 Reduced 12.85%	15,600 $626,000
Q3 2022 Nov 14, 2022	SELL	$36.93 - $56.68 $2.7 Million - $4.15 Million	-73,200 Reduced 80.35%	17,900 $784,000

528

119M

308K

191K

Ticker NTRA
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 96,957,400
Market Cap $16.3B
Description
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify sing...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.